Previous work has demonstrated that the SET antagonist FTY720 activates PP2A, is cytotoxic to primary chronic lymphocytic leukemia cells, and decreases lymphoma xenograft tumor growth [41, 42]. This evidence concerns the gene SET and B-cell chronic lymphocytic leukemia.